A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2016
At a glance
- Drugs VP 20621 (Primary)
- Indications Clostridium infections
- Focus Adverse reactions
- Sponsors Shire
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Apr 2013 Results published in the Media Release.
- 22 Apr 2013 Results were reported in a ViroPharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History